Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the...
The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW YORK, June 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a...
The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints NEW YORK, May 3, 2022 /PRNewswire/ -- Hoth...
HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and traumatic brain injury NEW YORK,...
